1-(N-phenylaminoalkyl)piperazine derivatives substituted at posi

Details 1-(N-phenylaminoalkyl)piperazine derivatives substituted at posi 1-(N-phenylaminoalkyl)piperazine derivatives substituted at posi

1998-07-31

2000-06-06

Shah, Mukund J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

544359, A01N 4360, A01N 31495, C07D40300

Patent

active

060719206

ABSTRACT:
Disclosed herein are novel compounds and methods for the treatment of disorders of the lower urinary tract. The novel compounds are aniline derivatives substituted at position 2 of the aniline ring. The methods comprise the administration of the novel compounds of the invention, and other compounds that bind to 5HT.sub.1A receptors, for treating disorders of the lower urinary tract.

REFERENCES:
patent: 3472854 (1969-10-01), Archer et al.
patent: 3635976 (1972-01-01), Shetty
patent: 4017624 (1977-04-01), Maruyama et al.
patent: 4060526 (1977-11-01), Shetty
patent: 4085107 (1978-04-01), Shetty
patent: 4205173 (1980-05-01), Shetty
patent: 5008267 (1991-04-01), Katakami et al.
patent: 5332739 (1994-07-01), Katakami et al.
Anderson, K.E., Drugs, 35:447-494, (1988).
Bliss, C.I., Quart. J. Pharm. Pharmacolo. 11, 192-216, (1938).
Boong Kwon, H. et al., J. Org. Chem., 55:3114-3118, (1990).
Cheng, Y.C., et al., Biochem. Pharmacol., 22:, 3099-3108, (1973).
Craig A,.et al., J. Life Sci. 38, 117-127, (1985).
De Groat, W.C., Neurobiology of Incontinence, Ciba Foundation Symposium 151:27-56, (1990).
De Lean, A., et al., Am. J. Physiol., 235:E97-E102, (1978).
Diop L, et al., J. Neurochem., 41, 710-715, (1983).
Doleschall, G., et al., Tetrahedron, 32, 57-64, (1976).
Dray, A., J. Pharmacol. Methods, 13: 157-165, (1985).
Fargin, A., et al., Nature 335:358-360, (1988).
Francher D.E., et al., J. Med. Chem., 7:721-725, (1964).
Guarneri, L., et al., Drugs of Today, 30:91-98, (1994).
Guarneri, L., et al., Pharmocol. Res., 27:173-187, (1993).
Guarneri, L. et al., Pharmacol. Res., 24:175-187, (1991).
Lepor, H., Urology, 42:483-501, (1993).
Maggi, C.A. et al., Brain Res., 380:83-93, (1986).
Maggi, C.A. et al., J. Pharmacol. Exp. Ther., 230:500-513, (1984).
March, J., Advanced Org. Chem., 4th Ed., 1041-1042, (1992).
McGuire, M.A., et al., J. Org. Chem., 59:6683-6686, (1994).
McGuire, E.J., Campbell's Urology 5th Ed., 616-638, (1986).
Moser, R.C., Eur J. Pharmacol. 193:165-172, (1991).
Ramage, G.R., et al., J. Chem. Soc., 4406-4409, (1952).
Ruffman, J. Int. Med. Res., 16:317-330, (1988).
Sugasawa, T., et al., Chem. Pharm. Bull., 33:1826-1835, (1985).
S.N., Synlett, Note 12:328, (1996).
Tricklebank et al. Euro. J. Pharmacol., 117:15-24, (1985).
Wu, Y.H. et al., J. Med. Chem., 12:876-881, (1969).
Adachi et al., Chem. Pharm. Bulletin, 33: 1826-1835.

Affiliated with

Also associated with

Rating

1-(N-phenylaminoalkyl)piperazine derivatives substituted at posi does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 1-(N-phenylaminoalkyl)piperazine derivatives substituted at posi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-(N-phenylaminoalkyl)piperazine derivatives substituted at posi will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2213814